AuraTracer智迹闻
中文

EVENT DOSSIER

Jialiang Brain Science has successfully completed two rounds of financing, C and D, with investments from Qiming Venture Capital and others.

2026-09-08 08:00 Industry & Investment 🔥 42.2 heat score
1sources
1days unfolding
42.2heat score
5mentions
SummaryAI generated

On September 8, 2026, according to TechWeb, Jialiang Brain Science successfully completed Series C and D financings. This financing was carried out by several well-known investment institutions, including Qiming Venture Capital.

Related eventsRELATED EVENTS
Key entitiesKEY ENTITIES
Cao PengJia Liang Brain ScienceQiming Venture CapitalSai Zhi Bo LeYuhang Guotou

Event frameEVENT FRAME

Funding / M&A 数亿元人民币

佳量脑科学 连续完成C、D轮融资

Coverage · reports per dayLANGUAGE SPLIT

Entity relations
Cao Peng × Jia Liang Br…1Cao Peng × Qiming Ventu…1Cao Peng × Sai Zhi Bo Le1Cao Peng × Yuhang Guotou1Jia Liang Brain Science…1Jia Liang Brain Science…1

SignalsSIGNALS

Keyword heat
  • Jia Liang Brain Science1
  • Qiming Venture Capital1
  • Yuhang Guotou1
  • Sai Zhi Bo Le1
  • Cao Peng1

All reports (1)SOURCES

T TechWeb·滚动 zh 2026-09-08 08:00

佳量脑科学连续完成C、D轮两轮融资,启明创投等投资

杭州佳量脑科学股份有限公司连续完成C轮及D轮融资,累计融资金额达数亿元人民币。C轮融资由启明创投领投,老股东余杭国投、辰德资本继续投资;D轮融资由赛智伯乐、宽桥恒松及宁波国资等多家机构共同参与。本轮融资后,公司将围绕商业化与国际化持续投入,加快推进Epilcure™注册上市及Vivastep™等下一代神经接口产品的临床转化,依托杭州与新加坡双中心布局建立国际市场体系。目前,公司已获得4张国家三类医疗器械注册证,覆盖脑电采集、精准定位和微创治疗等关键环节,并与全国50余家三甲医院建立临床合作网络。创始人曹鹏表示,公司正从证明技术可行转向证明产品价值,致力于构建面向重大神经疾病的技术与产品体系,推动中国原创神经医学技术进入更多医院和患者的治疗场景。